PDS Biotechnology Corporation (PDSB)
| Market Cap | 50.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -40.56M |
| Shares Out | 37.41M |
| EPS (ttm) | -1.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 180,456 |
| Open | 1.450 |
| Previous Close | 1.420 |
| Day's Range | 1.340 - 1.480 |
| 52-Week Range | 1.251 - 6.680 |
| Beta | 1.88 |
| Analysts | Strong Buy |
| Price Target | 14.00 (+944.78%) |
| Earnings Date | Mar 26, 2025 |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunolog... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 944.78% from the latest price.
News
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET
Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation Discussion topics to include pathology and prev...
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer...
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time
PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune ® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complete ...
PDS Biotechnology: Continuing The Holding Pattern
PDS Biotechnology is focusing on an HPV-directed immunotherapy as its main near-term hope, with new data presented at the ESMO Congress. Strengths include promising clinical data and a focused pipelin...
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)
PDS Biotechnology Corporation (NASDAQ:PDSB) Clinical Program Update Conference Call August 1, 2024 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Frank Bedu-Addo - Chief Executive Offi...
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J.
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 2024 (...
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immu...
PDS Biotechnology Announces Details of Virtual KOL Event
Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024 Virtual Webinar Updated ...
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immu...
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial
PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
Unique mechanism of action of the combination of PDS01ADC and Versamune ® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline ...
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
Preclinical research published in Vaccines demonstrates Infectimune ® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants
PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data
Preliminary efficacy results from phase 1/2 Mayo Clinic study, using PDS0101 + KEYTRUDA to treat patients with Oropharyngeal cancer, expected in Q2 2024. The global oral cancer treatment market is exp...
PDS Biotech Announces Retirement of Lauren V. Wood, M.D.
Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company Board-certified oncologist and hemat...